Aflibercept (Zaltrap®)

Assessment Status NCPE Assessment Process Complete
Drug Aflibercept
Brand Zaltrap®
Indication For the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Assessment Process
Rapid review commissioned 21/03/2013
Rapid review completed 10/04/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 04/10/2013
NCPE assessment completed 12/02/2014
NCPE assessment outcome Reimbursement Recommended

The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.

Technical Summary